Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navlimetostat plus nab-paclitaxel/gemcitabine versus placebo plus nab-paclitaxel/gemcitabine in first-line metastatic MTAP-deleted pancreatic ductal adenocarcinoma
2025-522598-12-00Phase 3Authorised
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 36
01
Overview
Phase 3, randomised, double-blind trial in pancreatic adenocarcinoma (PDAC) comparing Navlimetostat + nab-paclitaxel + gemcitabine with Placebo + nab-paclitaxel + gemcitabine (2 arms). Primary endpoint: Progression-free survival and overall survival. Planned start Dec 2025; status: authorised.
02
Drugs
navlimetostat
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2025-522598-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522598-12-00.